• Skip to content

Ceramisphere Health

<!-- Global site tag (gtag.js) - Google Analytics --> <script async src="https://www.googletagmanager.com/gtag/js?id=UA-163800918-1"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-163800918-1'); </script>

  • Home
  • About
    • Ceramisphere Health
    • History
    • People
    • Facilities
    • Technology
      • Ceramisphere Encapsulation Technology
      • Key Features and Benefits
  • Pipeline
    • Pipeline Overview
    • Lidocaine Patch
    • Controlled Drug Patch
    • EGF Patch
  • Investors
    • Technology Summary
    • Opportunity
    • Market & Opportunity for Lidocaine Patches
    • Market & Opportunity for Fentanyl Patches
    • Market & Opportunity for EGF Patches and Bioactive Wound Dressings
  • News
  • Downloads
  • Contact

Lidocaine Patch

Lidocaine Patch

Lidocaine Patch

We have developed a lidocaine nanocomposite patch using our innovative nanocomposite patch technology which offers a tangible and better alternative to currently available options.

WHY A LIDOCAINE PATCH?

  • A quick route to the market: Lidocaine has proven safety profile for the treatment of post-herpetic neuralgia (PHN) (Lidoderm®, Versatis®). All components of our patch are FDA approved for topical/transdermal applications would further expedite regulatory processes.
  • To prove the safety of our nanocomposite patch system: In addition to expediting our patch development through early clinical stages, this will also provide a clean baseline to showcase the potential of this novel delivery system.
  • Growing market: Representing roughly a market of 1 billion USD (IMS health 2015), the lidocaine market continues to grow, driven by an ageing population. There is growing evidence that lidocaine based pain relief can be used for other neuropathies e.g. diabetic foot.
  • Need for a differentiator technology: With the European patent (for Versatis®) expiry in 2017, companies are actively looking for a technology that could give them an edge over the generics.

OUR SOLUTION

  • The current lidocaine patch uses a high dose of drug with ~97% remaining in the used patch when discarded. It can only be applied for 12 H with a 12H break due to adverse skin reaction to high levels of lidocaine in the patch.
  • We have produced a highly efficient and biocompatible nanocomposite lidocaine patch: It has the potential for >24H application with the similar release rates as obtained with the current commercial patches. This is achieved using 30x lower dose with less than 5% leftover after use.
CERAMISPHERE HEALTH
ADVANCED DRUG DELIVERY
We are an Australian based drug delivery company focused on the development of our “zero-waste” transdermal patches for the delivery of analgesics with an emphasis on controlled drugs for pain-relief and for development of smart bioactive wound care products with minimal pain and scarring. We are seeking partners to help us progress our “zero-waste” nanocomposite patch technology through early clinical trials with a view to license the technology for specific therapeutic applications to patch or wound dressing manufacturers or pharmaceutical companies.
Read More
  • Home
  • About
  • Contact
  • Downloads
COPYRIGHT © CERAMISPHERE 2023
Privacy Policy Terms & Conditions